Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002918367 | SCV003256572 | pathogenic | Osteogenesis imperfecta type I | 2021-12-19 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the COL1A1 protein in which other variant(s) (p.Gly338Ser) have been determined to be pathogenic (PMID: 16786509, 17078022, 24668929; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant disrupts the triple helix domain of COL1A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL1A1, variants affecting these glycine residues are significantly enriched in individuals with disease (PMID: 9016532, 17078022) compared to the general population (ExAC). This variant has been observed in individual(s) with osteogenesis imperfecta (Invitae). This variant is not present in population databases (gnomAD no frequency). This variant, c.1005_1013del, results in the deletion of 3 amino acid(s) of the COL1A1 protein (p.Thr337_Pro339del), but otherwise preserves the integrity of the reading frame. |